Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B02BX06	HEMLIBRA	BioTech	Emicizumab - 30mg/ml	30mg/ml	Injectable solution	224,585,721 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 150mg/ml	150mg/ml	Injectable solution	895,547,224 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 105mg/0.7ml	105mg/0.7ml	Injectable solution	722,177,054 L.L
J07BC02	HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED	BioTech	Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 0.5ml/dose	0.5ml/dose	Injectable suspension	1,777,904 L.L
J07BC02	HEALIVE-HEPATITIS A VACCINE (HUMAN DIPLOID CELL) INACTIVATED	BioTech	Hepatitis A, inactivated antigen (TZ84 Strain), human diploid cell - 1ml/dose	0.5ml/dose	Injectable suspension	2,257,655 L.L
A10AB01	HUMULIN R U-100	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	701,486 L.L
A10AB04	HUMALOG KWIKPEN	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable solution	3,950,897 L.L
A10AB04	HUMALOG	BioTech	Insulin lispro - 100IU/ml	100IU/ml	Injectable suspension	1,988,887 L.L
A10AD01	HUMULIN 70/30	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
A10AD04	HUMALOG MIX 50 KWIKPEN	BioTech	Insulin lispro solution - 50%, Insulin lispro protamine suspension - 50%	100IU/ml	Injectable suspension	3,950,897 L.L
A10AD04	HUMALOG MIX 25 KWIKPEN	BioTech	Insulin lispro solution - 25%, Insulin lispro protamine suspension - 75%	100IU/ml	Injectable suspension	3,950,897 L.L
J07CA09	HEXAXIM	BioTech	Diphteria Toxoid - ?20IU/0.5ml, Tetanus toxoid - ?40IU/0.5ml, Bordetella Pertussis Antigens: toxoid - 25mcg/0.5ml, Bordetella Pertussis Antigens: filamentous haemagglutinin - 25mcg/0.5ml, Polio virus inactivated type 1 (Mahoney strain) - 40D antigen units/0.5ml, Polio virus inactivated type 2 (MEF-I strain) - 8D antigen units/0.5ml, Polio virus inactivated type 3 (Saukett strain) - 32D antigen units/0.5ml, Hepatitis B, surface antigen - 10mcg/0.5ml, H. Influenza type b polysaccharide1 ,2 - 12mcg/0.5ml, 1 conjugated to tetanus protein - 22-36mcg, 2 adsorbed on aluminium hydroxide hydrated, Al+++ - 0.6mg		Injectable suspension	4,462,901 L.L
A10AE01	HUMULIN N U-100	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable suspension	701,486 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 4,000IU	4,000IU	Injectable freeze dried substance+diluent	940,690 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 4,000IU	4,000IU	Injectable freeze dried substance+diluent	33,852,747 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 10,000IU	10,000IU	Injectable freeze dried substance+diluent	2,490,140 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 20,000IU	20,000IU	Injectable freeze dried powder + diluent	5,438,531 L.L
B03XA01	HEMAX	BioTech	Erythropoietin recombinant human (Epoetin alfa) - 40,000IU	40,000IU	Injectable freeze dried powder + diluent	6,316,060 L.L
H01AC01	HHT	BioTech	Somatropin recombinant - 16IU (5.32mg)	16IU (5.32mg)	Injectable freeze dried powder + diluent	4,078,562 L.L
L01FD01	HERCEPTIN	BioTech	Trastuzumab - 440mg	21mg/ml	Injectable concentrated powder for solution+diluent	166,423,476 L.L
L01FD01	HERCEPTIN	BioTech	Trastuzumab - 440mg	21mg/ml	Injectable concentrated powder for solution+diluent	166,423,476 L.L
L01FD01	HERZUMA	BioTech	Trastuzumab - 440mg	440mg	Injectable powder for concentrate for solution	89,046,707 L.L
L04AB04	HUMIRA	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	L.L
L01FD01	HERZUMA	BioTech	Trastuzumab - 150mg	150mg	Injectable powder for concentrate for solution	36,113,036 L.L
B02BX06	HEMLIBRA	BioTech	Emicizumab - 30mg/ml	30mg/ml	Injectable solution	L.L
L04AB04	HUMIRA	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	34,045,375 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg	40mg	Injectable solution	28,611,772 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg	40mg	Injectable solution	28,611,772 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	52,871,023 L.L
L04AB04	HYRIMOZ	BioTech	Adalimumab - 40mg/0.4ml	40mg/0.4ml	Injectable solution	52,871,023 L.L